Fig. 2.

Characterization of the DLG matrix. a The formation of a DLG matrix using the dual syringe kit. The outer layer LG35/65 was loaded with Rose Bengal and the inner layer LG50/50 was loaded with Methylene Blue for better illustration. b In vivo infrared thermal images of the tumor surgical sites in 4T1-bearing mice irradiated immediately after being treated with PBS, blank DLG, Free SG solution, and LG50/50 + SG@LG35/65. Images were recorded at 0 min, 2 min, 5 min, 10 min, and 20 min after 808 nm laser irradiation. c Manually controlled temperature increase in the tumor resection sites on 4T1 tumor-bearing mice, where different formulations were injected, by tuning the NIR laser irradiation for 10 min. d The photothermal controlled cumulative release profiles of sorafenib and the long-term sustained cumulative release profiles of IgG from the DLG matrix. Data are shown as means ± SEM (n = 3). e Fluorescence IVIS images depicting the in vivo retention of Ce6 fluorescence in mice injected with Ce6 solution (Free Ce6), and DLG matrix (CG@lg35/65 + AFIgG@LG50/50) with (DLG + L) or without (DLG-L) the NIR irradiation. f Mean fluorescence intensity (MFI) of corresponding fluorescence IVIS images in (e). g Fluorescence IVIS images depicting the in vivo retention of AFIgG fluorescence in mice injected with AFIgG solution (Free AFIgG), and DLG matrix (CG@lg35/65 + AFIgG@LG50/50) with (DLG + L) or without (DLG-L) the NIR irradiation. H) MFI of corresponding fluorescence IVIS images in (G). Data are shown as means ± SEM (n = 3). NIR laser: 808 nm